European Penny Stocks Under €200M Market Cap To Watch

As the European markets experience a boost with the pan-European STOXX Europe 600 Index rising 0.90% amid easing inflation and supportive monetary policy from the European Central Bank, investors are looking for opportunities beyond traditional investments. Penny stocks, often representing smaller or newer companies, continue to capture attention due to their potential for significant returns when backed by strong financials. While the term 'penny stock' might seem outdated, these investments remain relevant today as they offer unique opportunities for those seeking hidden value in quality companies.

Top 10 Penny Stocks In Europe

Click here to see the full list of 444 stocks from our European Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Pharming Group (ENXTAM:PHARM)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Pharming Group N.V. is a biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for rare diseases globally, with a market cap of €694.19 million.

Operations: The company generates revenue primarily from its Recombinant Human C1 Esterase Inhibitor Business, amounting to $320.71 million.

Market Cap: €694.19M

Pharming Group, a biopharmaceutical company with a market cap of €694.19 million, has shown significant revenue growth, reporting US$79.09 million in Q1 2025 sales compared to US$55.59 million the previous year. Despite being unprofitable with a net loss of US$14.72 million for the quarter, it maintains over three years of cash runway and positive free cash flow. The company's debt-to-equity ratio has improved significantly from 104.9% to 41.1% over five years, and its short-term assets exceed liabilities by a substantial margin, indicating strong financial management amid high share price volatility and executive board changes.

• Jump into the full analysis health report here for a deeper understanding of Pharming Group.
• Gain insights into Pharming Group's outlook and expected performance with our report on the company's earnings estimates.

Arbona (NGM:ARBO A)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Arbona AB (publ) is an investment company focusing on small and medium-sized listed and unlisted companies in Sweden, with a market capitalization of approximately SEK1.70 billion.

Operations: Arbona's revenue is primarily derived from three segments: Industry (SEK505.74 million), Transportation Technology (SEK120.59 million), and Properties (SEK9.88 million).

Market Cap: SEK1.7B

Arbona AB, with a market cap of SEK1.70 billion, focuses on investments in small and medium-sized companies. Despite trading at 36.8% below estimated fair value, its recent performance shows challenges such as negative earnings growth over the past year and lower profit margins compared to last year. However, Arbona's financial stability is underscored by satisfactory net debt to equity ratio (0.2%) and adequate coverage of short-term liabilities by assets (SEK412.4 million vs SEK171 million). The company's earnings have grown significantly over five years but were impacted by a large one-off gain of SEK162.3 million recently.

• Take a closer look at Arbona's potential here in our financial health report.
• Examine Arbona's past performance report to understand how it has performed in prior years.

Ekobox (WSE:EBX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Ekobox S.A. is an engineering company based in Poland with a market capitalization of PLN70.17 million.

Operations: The company's revenue is derived entirely from the Heavy Construction segment, amounting to PLN43.40 million.

Market Cap: PLN70.17M

Ekobox S.A., with a market cap of PLN70.17 million, operates in the Heavy Construction sector and recently reported a decline in quarterly revenue to PLN6.05 million from PLN10.28 million year-on-year, resulting in a net loss of PLN0.35 million. Despite challenges like high share price volatility and low return on equity (14.3%), Ekobox maintains financial stability with short-term assets exceeding both its short-term (PLN4.8M) and long-term liabilities (PLN2.4M). The company's debt levels have decreased significantly over five years, supported by robust operating cash flow coverage of its debt at 738.4%.

• Get an in-depth perspective on Ekobox's performance by reading our balance sheet health report here.
• Assess Ekobox's previous results with our detailed historical performance reports.

Where To Now?

• Dive into all 444 of the European Penny Stocks we have identified here.
• Ready To Venture Into Other Investment Styles? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com